With cardiovascular disease continuing to present a significant health concern, EPR’s Hannah Balfour reflects on recent development efforts and drug approvals in the space with comment from Dr Douglas Clark of Boehringer Ingelheim.

Learn about the common misconceptions surrounding eConsent, as well as the benefits they can realise through a digitally-enabled approach.

Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.

With demand for biopharmaceuticals rising and advances being made in bioseparation systems, the global market it expected to witness significant growth.

Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.